# Blinatumomab added to frontline chemotherapy

Source: https://onco.cc/pairings/blinatumomab-frontline-consolidation/  
OnCo record `blinatumomab-frontline-consolidation` (Pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Interleaving an immunotherapy with standard chemotherapy cycles improves survival in adults and children with newly diagnosed ALL.

## Summary

Adding blinatumomab, a CD19-directed bispecific T-cell engager, to frontline chemotherapy cycles is a combination pairing that improves survival in both adults and children with newly diagnosed B-cell acute lymphoblastic leukaemia. Chemotherapy reduces the bulk of disease and the immunosuppressive burden, after which blinatumomab engages the patient's recovering T cells against residual CD19-positive blasts. Two phase 3 trials, ECOG-ACRIN E1910 in adults who were already in MRD-negative remission and Children's Oncology Group AALL1731 in children with standard-risk disease, were both stopped early because of benefit. Blinatumomab is now a standard part of consolidation regardless of MRD status, and the linked papers describe both trials.

## Fields

- Kind: Pairing
- Last checked: 2026-09-07
- Pairs: Blinatumomab + Cytarabine + anthracycline ('7+3')
- Type: combination
- Rationale: Chemotherapy reduces bulk and immunosuppressive burden; blinatumomab then engages the patient's recovering T cells against residual CD19+ blasts.
- Evidence: Two positive phase 3 trials.

## Sources

- ClinicalTrials.gov NCT02003222: ECOG-ACRIN E1910: https://clinicaltrials.gov/study/NCT02003222
- ClinicalTrials.gov NCT03914625: COG AALL1731: https://clinicaltrials.gov/study/NCT03914625

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Standard-risk B-cell acute lymphoblastic leukaemia in children](https://onco.cc/cancers/all-paediatric-standard-risk/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/), [Cytarabine + anthracycline ('7+3')](https://onco.cc/drugs/cytarabine-7-3/)
- trials: [COG AALL1731](https://onco.cc/trials/aall1731/), [ECOG-ACRIN E1910](https://onco.cc/trials/e1910/)
- key papers: [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/blinatumomab-frontline-consolidation.json